Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis

Histopathology

Volumn 57, Issue 3, 2010, Pages 418-426

  Marx, Andreas H ^a   Zielinski, Margarete ^a   Kowitz, Charlotte Marie ^a   Dancau, Ana Maria ^a   Thieltges, Sabrina ^a   Simon, Ronald ^a   Choschzick, Matthias ^a   Yekebas, Emre ^a   Kaifi, Jussuf T ^a   Mirlacher, Martina ^a   Atanackovic, Djordje ^a   Brümmendorf, Tim H ^a   Fiedler, Walter ^a   Bokemeyer, Carsten ^a   Izbicki, Jakob R ^a   Sauter, Guido ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Barrett's adenocarcinoma; EGFR; FISH; TMA

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

RATTUS;

EID: 77956626969     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03643.x     Document Type: Article

References (51)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991 265 1287 1289.
2. Headrick Jr. Nichols FC III., Miller DL et al. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy. Ann. Thorac. Surg. 2002 73 1697 1702.
3. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol. 2005 92 151 159.
4. Carpenter G, Cohen S. Epidermal growth factor. J. Biol. Chem. 1990 265 7709 7712.
5. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 1986 46 4726 4731.
6. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005 227 9 23.
7. Normanno N, Bianco C, Strizzi L et al. The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets 2005 6 243 257.
8. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005 5 341 354.
9. Ebi N, Semba H, Tokunaga SJ et al. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J. Thorac. Oncol. 2008 3 1166 1171.
10. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008 372 1809 1818.
11. Jhawer M, Goel S, Wilson AJ et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008 68 1953 1961.
12. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 2008 26 5705 5712.
13. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009 27 579 584.
14. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol. Oncol. 2008 110 49 55.
15. Kreisl TN, Lassman AB, Mischel PS et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 2009 92 99 105.
16. Javle M, Pande A, Iyer R et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am. J. Clin. Oncol. 2008 31 329 334.
17. Guarino MJ, Schneider CJ, Hosford MA et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist 2009 14 119 124.
18. Goncalves A, Fabbro M, Lhomme C et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol. Oncol. 2008 108 42 46.
19. Dickler MN, Rugo HS, Eberle CA et al. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 2008 14 7878 7883.
20. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 2008 26 5603 5609.
21. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004 351 337 345.
22. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005 23 1803 1810.
23. Miller VA, Riely GJ, Zakowski MF et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol. 2008 26 1472 1478.
24. Nagahara H, Mimori K, Ohta M et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin. Cancer Res. 2005 11 1368 1371. (Pubitemid 40315215)
25. Tsuchihashi Z, Khambata-Ford S, Hanna N, Janne PA. Responsiveness to cetuximab without mutations in EGFR. N. Engl. J. Med. 2005 353 208 209.
26. Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 2008 19 717 723.
27. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008 52 738 746.
28. Zhu CQ, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008 26 4268 4275.
29. Dziadziuszko R, Holm B, Skov BG et al. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann. Oncol. 2007 18 447 452.
30. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008 359 1757 1765.
31. Tol J, Koopman M, Cats A et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009 360 563 572.
32. Wang KL, Wu TT, Choi IS et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007 109 658 667.
33. Wilkinson NW, Black JD, Roukhadze E et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J. Gastrointest. Surg. 2004 8 448 453.
34. Yacoub L, Goldman H, Odze RD. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. Mod. Pathol. 1997 10 105 112.
35. Miller CT, Moy Jr. Lin L et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin. Cancer Res. 2003 9 4819 4825.
36. Rygiel AM, Milano F, Ten Kate FJ et al. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 2008 17 1380 1385.
37. al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int. J. Cancer 1993 54 213 219.
38. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 2001 93 1141 1146.
39. Daniele L, Cassoni P, Bacillo E et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J. Thorac. Oncol. 2009 4 684 688.
40. Hamilton SR, Aaltonen LA eds. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000.
41. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol. Med. 2005 114 257 268.
42. Bhargava R, Gerald WL, Li AR et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol. 2005 18 1027 1033.
43. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004 350 2129 2139.
44. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am. J. Surg. Pathol. 2005 29 1145 1151.
45. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 2007 60 768 772.
46. Ferry DR, Anderson M, Beddard K et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin. Cancer Res. 2007 13 5869 5875.
47. Helfrich BA, Raben D, Varella-Garcia M et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin. Cancer Res. 2006 12 7117 7125.
48. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 2009 27 1323 1333.
49. Puhringer-Oppermann FA, Stein HJ, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis. Esophagus 2007 20 9 11.
50. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007 98 1817 1824.
51. Tzeng CW, Frolov A, Frolova N et al. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007 141 464 469.